HOME DCVAX ® TECHNOLOGY PRODUCT CANDIDATES CLINICAL TRIALS INVESTORS & MEDIA ABOUT US > Our Technology DCVax® is a platform technology that uses activated dendritic cells Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused on the development of personalized cancer vaccines designed to treat a broad range of solid tumor cancers. Read more about NW Bio >> Latest Videos Clinical Trial Program Update: Presentation by Dr. Marnix Bosch at ASCO 2019 Click on arrows to view full-screen video. Download Presentation Recent Presentations & Interviews 11 DEC 2019 Dr. Bosch’s Presentation at GBM Drug Development Summit in Boston: DCVax®-L Phase III Trial, “Where Are We, And How Did We Get Here?” 03 JUN 2019 Clinical Trial Program Update: Presentation by Dr. Marnix Bosch at ASCO 2019 Press Releases 29 NOV 2021 Northwest Biotherapeutics Announces $15 Million Financing 28 OCT 2021 Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility Follow us On: DCVAX® TECHNOLOGY About DCVax® Dendritic Cell Immunotherapy Patient Stories & Physician Comments PRODUCT CANDIDATES DCVax® – L DCVax® – Direct DCVax® – Prostate CLINICAL TRIALS Pipeline DCVax® – L Phase III DCVax® – Direct Phase I/II INVESTORS & MEDIA Contacts SEC Filings Stock Information Press Releases Webcasts ABOUT US Overview Company Management Publications Related Links Contact Us © 2017 Northwest Biotherapeutics, Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 Phone: 240-497-9024 Forward-looking Statement Legal Disclaimer Privacy Policy